Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer
NCT06005740 · View on ClinicalTrials.gov ↗
Study Summary
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-4-500 in patients with advanced cancer. For Part 1, any advanced or metastatic solid tumor malignancy will be evaluated including, for example, adrenocortical carcinoma (ACC).
Conditions Studied
Interventions
- DRUG TORL-4-500
Study Locations (10)
California
- Providence Medical Foundation — Fullerton
- UCLA - JCCC Clinical Research Unit — Los Angeles
- Torrance Memorial Physician Network — Torrance
Florida
- Mayo Clinic Jacksonville — Jacksonville
- Florida Cancer Specialists Lake Nona Drug Development Unit — Orlando
Arizona
- Mayo Clinic Phoenix — Phoenix
Minnesota
- Mayo Clinic Rochester — Rochester
Virginia
- Virginia Cancer Specialists — Lexington
Ontario
- University Health Network, Princess Margaret Cancer Centre — Toronto
Quebec
- McGill University Health Centre — Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2023-12-04 |
| Est. Completion | 2026-10-31 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06005740
The ClinicalTrials.gov registry entry for NCT06005740 describes a study currently listed as recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is TORL Biotherapeutics, which has 7 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with Advanced Solid Tumor appearing as the primary indexed condition, and to 1 intervention — of which TORL-4-500 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06005740 reports 10 study locations spanning 7 distinct geographic areas — top geographies include California, Florida, Arizona. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06005740 about?
NCT06005740 is a clinical study titled "A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer". This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-4-500 in patients with advanced cancer. For Part 1, any advanced or metastatic solid tumor malignancy will be evaluated including, for example, adrenocortical carcinoma (ACC).
What is the current status of trial NCT06005740?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2023-12-04. Estimated completion is 2026-10-31.
What conditions does trial NCT06005740 study?
This clinical trial studies the following conditions: Advanced Solid Tumor, Hepatocellular Carcinoma. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06005740?
The interventions under investigation include: TORL-4-500 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06005740?
This trial is sponsored by TORL Biotherapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06005740 being conducted?
This trial has 10 study locations across Arizona, California, Florida, Minnesota, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.